Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres by 강석구 et al.
molecules
Article
Combinatorial Therapeutic Effect of Inhibitors of Aldehyde
Dehydrogenase and Mitochondrial Complex I, and the
Chemotherapeutic Drug, Temozolomide against
Glioblastoma Tumorspheres
Hun Ho Park 1,† , Junseong Park 2,3,† , Hye Joung Cho 2, Jin-Kyoung Shim 2, Ju Hyung Moon 2,
Eui Hyun Kim 2 , Jong Hee Chang 2, Soo Youl Kim 4 and Seok-Gu Kang 2,5,*


Citation: Park, H.H.; Park, J.;
Cho, H.J.; Shim, J.-K.; Moon, J.H.;
Kim, E.H.; Chang, J.H.; Kim, S.Y.;
Kang, S.-G. Combinatorial
Therapeutic Effect of Inhibitors of
Aldehyde Dehydrogenase and
Mitochondrial Complex I, and the
Chemotherapeutic Drug,
Temozolomide against Glioblastoma
Tumorspheres. Molecules 2021, 26,
282. https://doi.org/10.3390/
molecules26020282
Academic Editors: Simona Collina,
Mariarosaria Miloso and
Laura Cerchia
Received: 30 November 2020
Accepted: 5 January 2021
Published: 8 January 2021
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional clai-
ms in published maps and institutio-
nal affiliations.
Copyright: © 2021 by the authors. Li-
censee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Neurosurgery, Gangnam Severance Hospital, Yonsei University College of Medicine,
Seoul 06273, Korea; nshhp@yuhs.ac
2 Department of Neurosurgery, Brain Tumor Center, Severance Hospital,
Yonsei University College of Medicine, Seoul 03722, Korea; j.p@catholic.ac.kr (J.P.);
hjcho3633@yuhs.ac (H.J.C.); nanjk2@yuhs.ac (J.-K.S.); MJJR80@yuhs.ac (J.H.M.);
euihyunkim@yuhs.ac (E.H.K.); CHANGJH@yuhs.ac (J.H.C.)
3 Precision Medicine Research Center, College of Medicine, The Catholic University of Korea,
Seoul 06591, Korea
4 Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 10408, Korea;
kimsooyoul@gmail.com
5 Department of Medical Science, Yonsei University Graduate School, Seoul 03722, Korea
* Correspondence: seokgu9@yuhs.ac
† These authors contributed equally to this article.
Abstract: Resident cancer cells with stem cell-like features induce drug tolerance, facilitating survival
of glioblastoma (GBM). We previously showed that strategies targeting tumor bioenergetics present
a novel emerging avenue for treatment of GBM. The objective of this study was to enhance the
therapeutic effects of dual inhibition of tumor bioenergetics by combination of gossypol, an aldehyde
dehydrogenase inhibitor, and phenformin, a biguanide compound that depletes oxidative phospho-
rylation, with the chemotherapeutic drug, temozolomide (TMZ), to block proliferation, stemness,
and invasiveness of GBM tumorspheres (TSs). Combination therapy with gossypol, phenformin,
and TMZ induced a significant reduction in ATP levels, cell viability, stemness, and invasiveness
compared to TMZ monotherapy and dual therapy with gossypol and phenformin. Analysis of
differentially expressed genes revealed up-regulation of genes involved in programmed cell death,
autophagy, and protein metabolism and down-regulation of those associated with cell metabolism,
cycle, and adhesion. Combination of TMZ with dual inhibitors of tumor bioenergetics may, there-
fore, present an effective strategy against GBM by enhancing therapeutic effects through multiple
mechanisms of action.
Keywords: aldehyde dehydrogenase; bioenergenetics; glioblastoma; oxidative phosphorylation;
temozolomide; tumorsphere
1. Introduction
Despite improved standards of care, the survival rate of patients with glioblastoma
(GBM) remains poor [1,2]. Surgery is the most effective treatment for complete resection,
but unlike tumors of other organs, it is impossible to remove whole brain with tumors. Resi-
dent cancer cells with stem cell-like features and heterogeneity induce therapeutic tolerance
and relapse, facilitating glioblastoma (GBM) survival and proliferation characterized by
GBM tumorspheres (TSs) [3–7]. In view of the limitations of surgery alone, temozolomide
(TMZ), an alkylating agent, in conjunction with postoperative radiation is employed as
the standard of care for GBM. However, TMZ is insufficient for complete elimination of
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resistant GBM TSs. For these reasons, targeting the universal features of cancer cells is
an emerging therapeutic strategy to overcome resistance to conventional cancer therapy
and tumor recurrence [5–8]. Modulation of cancer cell metabolism through depletion of
glucose and oxidative phosphorylation, the main source of tumor energy, is one such novel
approach [9,10]. In addition, combining several therapeutic agents to inhibit multiple en-
ergy pathways may present a means to induce synergistic activity against resistant cancer
cells [11,12]. Previous studies by our group showed that dual inhibition of glycolysis and
oxidative phosphorylation could synergistically suppress GBM TSs [7,13–15]. Metformin
and phenformin are biguanides reported to induce energetic stress and glucose depletion
by inhibiting mitochondrial complex I and oxidative phosphorylation [7,13–17]. While
phenformin has shown to display greater anticancer activity and tissue availability than
metformin [17,18], its sole use has yielded disappointing results to date [19]. Gossypol is a
polyphenolic compound extracted from cottonseed known to exert anticancer effects by in-
hibiting aldehyde dehydrogenase (ALDH) and oxidative phosphorylation [20,21]. Similar
to phenformin, gossypol alone appears ineffective as a therapeutic agent for cancer [22–24].
In the present study, we aimed to overcome the weaknesses and enhance the therapeu-
tic effects of proven agents targeting tumor bioenergetics by combination with conventional
chemotherapeutic agent. The biological effects of combination drug administration with
gossypol, phenformin, and TMZ compared to TMZ alone as well as gossypol and phen-
formin dual therapy on GBM TSs were evaluated.
2. Results
2.1. Optimization of Gossypol, Phenformin, and TMZ Concentrations
Previously, we showed that gossypol (10 µM) and phenformin (10 µM) exert dual in-
hibitory biological effects without affecting cell viability [15]. The sublethal concentrations
of gossypol and phenformin as well as TMZ, alone and combined, were re-established
using the WST assay for sphere-cultured U87 and GBM TS (TS13-64) and according to
our previous findings [13]. TMZ monotherapy (250 µM), and dual therapy with gossypol
(10 µM) and phenformin (10 µM) exerted minimal effects on cell viability relative to con-
trol (>50%). Combined treatment with gossypol (10 µM), phenformin (10 µM), and TMZ
(250 µM) exerted significant synergistic effects on cell viability of sphere-cultured U87 and
GBM TS (TS13-64).
2.2. Combination Therapy Inhibits Cell Proliferation and Energy Metabolism
TMZ monotherapy and dual therapy with gossypol and phenformin induced signifi-
cant decrease in the proliferation of sphere-cultured U87 and GBM TS (TS13-64) compared
to the control group. Antiproliferative effects were significantly enhanced with the combi-
nation of gossypol, phenformin, and TMZ (Figure 1A). Marked decreases in ATP levels with
each agent alone and in combination, led to subsequent changes in cell viability (Figure 1B).
This finding confirms that the individual agents not only exert antiproliferative effects
through inhibition of cellular energy metabolism, but also that efficacy is enhanced with
the combination therapy. We observed no significant differences in cell viability between
TMZ monotherapy and gossypol/phenformin dual therapy. However, combination of
both therapies induced significantly greater antiproliferative effects than each agent alone.
Clearly, metabolic perturbations and energy stress at the cellular level need to be addressed
to improve the standard of care for GBM [7,13–15].
2.3. Combination Therapy Suppresses Stemness
Neurosphere formation assays were used to evaluate the effects of treatment on stem-
ness of sphere-cultured U87 and GBM TS (TS13-64) in relation to changes in the gene
expression profile. TMZ monotherapy, and gossypol/phenformin dual therapy exerted
equivalent stemness inhibition effects, as demonstrated by the reduced proportion of
sphere-positive wells (Figure 2A). Combined treatment of gossypol and phenformin with
TMZ led to remarkable enhancement of anti-stemness effects by almost completely inhibit-
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ing neurosphere formation compared to each treatment alone (Figure 2B,C). Interestingly,
expression of stemness-related markers, including CD133, nestin, PDPN, and Oct3/4
was considerably reduced by gossypol, phenformin, and TMZ, both alone and combined,
on western blots (Figure 2D,E). These results demonstrate that TMZ monotherapy and
gossypol/phenformin dual therapy efficiently suppress stemness on their own and com-
bining the two treatments enhances the therapeutic efficacy.




Figure 1. Biological effects on glioblastoma (GBM) tumorspheres (TSs) after combination drug administration of gossy-
pol, phenformin, and temozolomide (TMZ) compared to control, TMZ monotherapy, and gossypol/phenformin dual 
therapy. (A) Cell viability and (B) ATP levels of U87 (n = 4) and TS13-64 (n = 4) were measured 72 h after combination 
drug therapy (mean ± SD; asterisks over each bar represent statistically significant differences compared to control; * p < 
0.05, ** p < 0.01, *** p < 0.001). 
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The invasiv property of GBM TSs was evaluated using collagen-based 3D inva-
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into the collagen matrix. Both gossy ol/phenf rmin and TMZ, alone and in combination
induced marked suppression f invasiveness of sphere-cultured U87 and GBM TS (TS13-64)
(Figure 3A). Quantitative evaluation revealed that the anti-invasive effect of gossypol and
phenformin combined with TMZ was more significant than that of each therapy alone
(Figure 3B). Western blot analysis of esenchymal transition- and invasion-related markers
including N-cadherin, Snail, Twist, and Zeb1, revealed substantial decrease following
treatment with gossypol/phenformin and TMZ, alone or combined (Figure 3C,D). Consis-
tently, the efficacy of TMZ monotherapy and gossypol/phenformin dual therapy could be
enhanced by combining the two therapies together.
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(TS13-64) (Figure 3A). Quantitative evaluation revealed that the anti-invasive effect of 
gossypol and phenformin combined with TMZ was more significant than that of each 
therapy alone (Figure 3B). Western blot analysis of mesenchymal transition- and inva-
sion-related markers including N-cadherin, Snail, Twist, and Zeb1, revealed substantial 
decrease following treatment with gossypol/phenformin and TMZ, alone or combined 
(Figure 3C,D). Consistently, the efficacy of TMZ monotherapy and gossypol/phenformin 
dual therapy could be enhanced by combining the two therapies together. 
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** p < 0.01, *** p < 0.001).
2.5. Transcription Profiles Following Combination Therapy
Microarrays were used to evaluate changes in gene expression profiles after treatment
with gossypol, phenformin, and TMZ. Hierarchical clustering showed strong intragroup
clustering and distinct expression patterns compared with controls (Figure 4A). Notably,
stemness- and invasiveness-related genes were remarkably down-regulated by gossypol
and phenformin treatment, and these effects were further enhanced by TMZ combination
(Figure 4B). Functional annotation of differentially expressed genes (DEGs) using GO
database revealed distinct enriched gene sets. Genes up-regulated in the combination
group were related to programmed cell death, autophagy, and protein catabolism, whereas
down-regulated genes were associated with cell cycle and migration, which were consistent
with the previous findings (Figure 4C,D). These results suggest feasible action mechanisms
of the combinatorial therapeutic regimen.
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3. Discussion
The intrinsic tendency of GBM to infiltrate normal brain tissue renders complete
surgical resection of tumor an unattainable goal [25]. Several adjuvant strategies have been
proposed to overcome these limitations, but none have proved successful so far [26–28].
Thus, adjuvant therapy targeting resident cancer cells is crucial for reversing poor survival
rates. A significant subpopulation of GBM cancer cells that can survive conventional
chemotherapy is proposed to possess stem cell-like features and heterogeneity [3–8]. Ther-
apeutic tolerance and relapse of surviving cancer cells is fueled by glycolysis and oxidative
phosphorylation, known to serve as major suppliers of ATP for cancer cells [29–31]. In view
of these findings, the concept of modulating cancer metabolism by removing the energy
source of tumor cells is an emerging therapeutic strategy [9,10]. Combined treatment with
several therapeutic agents could induce synergistic inhibition of energy pathways [11,12].
However, successful clinical translation can only be achieved if the key molecules associ-
ated with cancer metabolism are identified for targeted therapy. Cancer cells utilize diverse
nutrients, such as glucose and NADH, to fuel oxidative phosphorylation [29,30]. There-
fore, induction of general metabolic stress via depletion of glucose and NADH present a
reasonable approach to provide a less favorable environment for the metabolically active
tumor cells [9,10].
We previously demonstrated that dual inhibition of glycolysis and oxidative phospho-
rylation could exert a synergistic effect with drugs against GBM TSs [7,13–15]. A newly
designed biguanide (HL 156A) combined with TMZ [13], metformin combined with
2-deoxyglucose [14], and phenformin combined with gossypol [15], synergistically re-
duced ATP levels, cell viability, stemness, and invasiveness of GBM TSs. In the present
study, we extended our previous research and examined the therapeutic effects of dual
inhibition of glycolysis and oxidative phosphorylation with gossypol and phenformin
in combination with the chemotherapeutic drug, TMZ. Biguanides such as metformin
and phenformin are inhibitors of mitochondrial complex I, known to suppress cancer cell
migration and proliferation [13–17,32]. Activated glycolytic metabolism is maintained via
active glycogen synthase in GBM TSs, which could be down-regulated with inhibitors of
gluconeogenesis targeting both mitochondrial and glycolytic pathways [32,33]. However,
the stand alone utility of biguanides for targeting cancer metabolism is limited and their
therapeutic effects against other cancers [12,19,20] and GBM TSs [13–15] could only be
enhanced by combination with other agents. Phenformin was selected over metformin
in this study owing to its superior bioavailability, potent inhibition of mitochondrial
complex I, and higher CSF concentration [16–18]. The hydrophilic nature of metformin
facilitates cellular entry specifically through organic cation transporters abundant in hep-
atocytes, but not elsewhere [18]. Gossypol is a naturally derived ALDH inhibitor that
can suppress NADH, which fuels oxidative phosphorylation critical for metabolism of
cancer cells [20,21]. Several isoforms of ALDH have been highlighted as potential drug
targets, considering the elevated ALDH expression in GBM TSs [15,34]. However, simi-
lar to biguanides, gossypol on its own is ineffective against GBM TSs [15,24] and other
cancers [22,23]. TMZ, a well-known conventional chemotherapeutic agent, is a crucial
component of the standard of care for GBM. Unfortunately, even among TMZ-responsive
patients, therapeutic tolerance and relapse can develop with consequent mortality [1,2].
According to our results, TMZ combined with gossypol and phenformin significantly and
synergistically suppressed ATP levels, cell viability, stemness, and invasiveness of GBM TSs
relative to treatment alone. Gossypol and phenformin induced superior ATP depletion and
reduction of cell viability than TMZ while TMZ induced superior suppression of stemness
and invasiveness of GBM TSs than gossypol and phenformin, albeit to a nonsignificant
extent. These results support the implementation of combined therapy to overcome the
weakness of stand-alone treatment and enhance the therapeutic effects of each agent in
a synergistic manner. The synergistic effects of combination therapy were further sup-
ported by the functional annotation of DEGs, showing up regulation of genes associated
with programmed cell death, autophagy and protein metabolism and down regulation
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of genes involved in cell metabolism, cycle and adhesion. The significant reduction of
stemness-, mesenchymal transition- and invasion-related markers observed via western
blot confirmed the above findings. The action mechanisms of gossypol/phenformin dual
therapy and TMZ monotherapy are complementary, whereby the therapeutic tolerance
is minimized and the synergistic efficacy maximized against GBM TSs. We anticipate to
validate the results of this study through an in vivo experiment with mouse orthotopic
xenograft models. The significance of the forthcoming experiments is bright considering
the fact that radiotherapy could also be combined to enhance the therapeutic effects of our
combinatorial therapeutic regimen.
Cancer stem cells (CSCs) are responsible for therapeutic tolerance and relapse of GBM
TSs and modulation of cancer metabolism. Inhibitory effects on stemness may, therefore,
serve as a promising therapeutic strategy [5–7]. Several reports have implicated a specific
subpopulation of CSCs in invasiveness of surviving cancer cells [35,36]. However, direct
evidence linking between CSCs and invasiveness is still lacking [37]. Moreover, limited
information is available on GBM-specific stem cell surface markers and further research
is warranted to identify potential therapeutic targets [38]. Data from the current study
support our previous finding that dual inhibition of tumor bioenergetics can be effectively
combined with established standard treatments. We conclude that dual inhibition of
glycolysis and oxidative phosphorylation with gossypol and phenformin in combination
with the chemotherapeutic drug, TMZ, presents a novel therapeutic approach against
therapeutic tolerance and relapse of GBM.
4. Materials and Methods
4.1. Cell Culture and Reagents
Two TS-forming GBM lines, U87 and TS13-64 were used for study. U87 spheres were
generated from the U87MG cell line under TS culture conditions. The molecular markers
of U87 cell line entailed no mutation of isocitrate dehydrogenase 1 and unmethylation
of O6-methylguanine DNA methyltransferase gene. Cells were cultured in TS complete
medium composed of Dulbecco’s modified Eagle’s medium/F12 (Mediatech, Manassas, VA,
USA), 1 × B27 (Invitrogen, San Diego, CA, USA), 20 ng/mL basic fibroblast growth factor,
and 20 ng/mL epidermal growth factor (Sigma-Aldrich, St. Louis, MO, USA). TS-forming
GBM cells (TS13-64) were established from fresh tissue specimens of a patient [13–15].
Detailed information of the tissue specimen entailed no mutation of isocitrate dehydro-
genase 1, unmethylation of O6-methylguanine DNA methyltransferase gene, no loss of
heterozygosity of chromosomes 1p and 19q, 20–30% positivity of p53, Ki-67 proliferation
index of 40–50%, and mutation of epidermal growth factor receptor. All experiments
were performed under TS culture condition. Gossypol and TMZ (MSD) were dissolved
in dimethyl sulfoxide (DMSO), and phenformin (Sigma-Aldrich) in H2O. The treatment
concentrations were as follows: 250 µM TMZ for mono treatment, 10 µM gossypol and
10 µM phenformin for dual treatment, and 10 µM gossypol, 10 µM phenformin and 250 µM
TMZ for combination treatment.
4.2. Evaluation of ATP Level and Cell Viability
Dispersed GBM TSs were seeded in 96-well plates at a density of 104 cells/well. ATP
levels were measured using a CellTiter-Glo luminescent cell viability assay kit (Promega,
Fitchburg, WI, USA). A 1.0-fold ATP level was defined as the mean, normalized value in
the control group. Cell viability was quantified using WST assay (Promega, Fitchburg,
WI, USA).
4.3. Neurosphere Formation Assay
Ten dissociated, single GBM TSs were seeded in 96-well plates and cultured for three
weeks with TS complete medium that was replenished every week. Images were cap-
tured and analyzed using ToupView software (version 3.7, ToupTek Photonics, Hangzhou,
Zhejiang, China).
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4.4. Invasion Assay
Each well of a 96-well plate was filled with mixed matrix composed of Matrigel, colla-
gen type I (Corning Inc., Corning, NY, USA), and TS complete medium. U87 tumorsphere
and TS13-64 cells grown as single spheroids were seeded inside the matrix prior to gelation.
TS complete medium was added over the gelled matrix to prevent drying and the invasion
area quantified as the occupied area at (72 h–0 h)/0 h.
4.5. Characterization of GBM Tumorspheres
TS formation was established from human GBM specimens as described previously [39].
GBM TSs used in the study were positive for markers of stemness, cluster of differentia-
tion (CD) 133, and nestin (Abcam, Cambridge, UK) in immunocytochemistry. GBM TSs
displayed evidence of neuroglial differentiation with expression of glial fibrillary acidic
protein (GFAP) (Dako, Carpinteria, CA, USA), myelin basic protein (MBP), neuronal nuclei
(NeuN), and tubulin beta 3 (TUBB3) (Chemicon, Temecula, CA, USA). GFAP and MBP
could not be detected in the U87 cell line.
4.6. Western Blot Analysis
Cell lysates were separated via sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis using 10% Tris-glycine gels. Protein bands were transferred to nitrocellu-
lose membranes and probed with antibodies against CD133, Nestin (Novus Biologicals,
Littleton, CO, USA), PDPN and Snail (Cell Signaling Technology, Berverly, MA, USA),
N-cadherin (R&D Systems, Minneapolis, MN, USA), Zeb1 (Sigma-Aldrich), Twist, Oct3/4,
and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Detection was performed
using horseradish peroxidase–conjugated IgG (Santa Cruz Biotechnology), in conjunction
with Western Lightning Plus-enhanced chemiluminescence reagent (PerkinElmer, Waltham,
MA, USA). Images were captured using ImageQuant LAS 4000 mini (GE Healthcare Life
Sciences, Little Chalfont, UK).
4.7. Gene Expression Microarray Datasets and Analysis
Total RNA from GBM TSs was extracted using a Qiagen RNeasy Plus Mini kit accord-
ing to the manufacturer’s protocol and loaded on the Illumina HumanHT-12 v4 Expression
BeadChip column (Illumina, San Diego, CA, USA). Data were processed, transformed,
and normalized with the quantile normalization method using the R/Bioconductor lumi
package [40]. Using GENE-E software (Broad Institute, Cambridge, MA, USA), average
linkage hierarchical clustering was performed with Pearson’s correlation as a distance met-
ric and expression levels depicted as heat maps. The functional annotation of DEGs (one-
way ANOVA with Tukey’s post hoc test; p < 0.001) was performed via over-representation
analysis using GO Biological Process gene sets and visualized as dot plots with Bonferroni-
adjusted P-value using the R/Bioconductor clusterProfiler package [41].
4.8. Statistical Analysis
Biological effects, stemness, and invasiveness of GBM TSs after combination drug
administration (gossypol/phenformin and TMZ) compared to control, TMZ monotherapy,
and gossypol/phenformin dual therapy groups were evaluated using one-way ANOVA
with Tukey’s post hoc test. Average linkage hierarchical clustering was performed with
Pearson’s correlation as a distance metric. Statistical significance for functional annotation
of DEGs was determined using the two-sided hypergeometric test and only nodes with
Bonferroni-adjusted p values of ≤ 0.05 displayed. All statistical analyses were performed
with SPSS software version 18.0 for Windows (SAS Institute, Inc., Chicago, IL, USA).
Two-tailed p values ≤ 0.05 were considered statistically significant.
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